Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)

Sponsor

Suzhou Kintor Pharmaceutical Inc, (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT03893695

Collaborator

(none)

Enrollment

Locations

Arm

Anticipated Duration (Months)

6.7

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This single arm, open label, two stage study will be conducted in several medical centers around Taiwan. Stage one determine safety and tolerability in patients with HCC, and stage two assess anti-tumor activities of GT90001 in combination with nivolumab in patients with metastatic HCC. Subjects who fulfill all the entry criteria and have written informed consent will be enrolled to the study.

Condition or Disease	Intervention/Treatment	Phase
Metastatic Hepatocellular Carcinoma HCC Combinations of Drugs; Dependence	Drug: GT90001 and Nivolumab	Phase 1/Phase 2

Detailed Description

Based on published and first-hand experience with the safety and tolerability of both GT90001 and nivolumab, the proposed dose is GT90001 7 mg/kg in combination with nivolumb 3 mg/kg. Nivolumab will first be administered by intravenous infusion over 60 minutes, then 30 minutes later, give GT90001 intravenous infusion for 1 hour. All participants will receive GT90001 + Nivolumab until unacceptable toxicity, disease progression or loss of clinical benefit as determined by the investigator.The primary objective of the study is to determine the safety and tolerability of GT90001 in combination with nivolumab in subjects with advanced and or metastatic HCC who were progressed on or were intolerant of first-line and/or second-line systemic therapy. The secondary objectives will be to evaluate the anti-tumor efficacy and the PK profile of this combination therapy.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

20 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

Single arm, Open label,Two stage studySingle arm, Open label,Two stage study

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma

Actual Study Start Date :

May 25, 2019

Anticipated Primary Completion Date :

Jun 25, 2022

Anticipated Study Completion Date :

Jun 25, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: metastatic HCC Stage one - Dose de-escalation: Each dose cohort will assess toxicity within the 28 days following the first dose of nivolumab and GT90001. Stage two- the expansion cohort: 14 patients will be enrolled to the expansion cohort where one or no DLT takes place in planned study cohort.	Drug: GT90001 and Nivolumab Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort. Other Names: GT90001 and Opdivo

Arm

Intervention/Treatment

Experimental: metastatic HCC

Stage one - Dose de-escalation: Each dose cohort will assess toxicity within the 28 days following the first dose of nivolumab and GT90001. Stage two- the expansion cohort: 14 patients will be enrolled to the expansion cohort where one or no DLT takes place in planned study cohort.

Drug: GT90001 and Nivolumab

Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.

Other Names:

GT90001 and Opdivo

Outcome Measures

Primary Outcome Measures

Dose-limiting Toxicity(DLT) [28 days]
Each dose cohort will initially include 6 evaluable patients for assessment of toxicity within the 28 days following the first dose of nivolumab and GT90001.

Secondary Outcome Measures

overall response rate (ORR) [2 years]
To estimate ORR, per RECIST 1.1 assessed by investigator review
the duration of response (DOR), [2 years]
To evaluate the DOR per RECIST 1.1 assessed by investigator review
disease control rate (DCR), [2 years]
To evaluate the DCR per RECIST 1.1 assessed by investigator review
time to response (TTR) [2 years]
To evaluate the TTR per RECIST 1.1 assessed by investigator review
progression-free survival (PFS) [2 years]
To evaluate the PFS per RECIST 1.1 assessed by investigator review
maximum concentration (Cmax) [2 years]
Pharmacokinetics
time that maximum concentration is observed (tmax) [2 years]
Pharmacokinetics
area under the concentration time-curve from time zero to infinity (AUC0∞) [2 years]
Pharmacokinetics
area under the plasma concentration-time curve from time zero hours to time (t hrs), (AUC0-t) [2 years]
Pharmacokinetics
area under the plasma concentration-time curve from time zero hours to 24 hours (AUC0-24) [2 years]
Pharmacokinetics
terminal elimination rate constant (λz) [2 years]
Pharmacokinetics
terminal elimination half life (t½) [2 years]
Pharmacokinetics
volume of distribution (Vz) [2 years]
Pharmacokinetics
volume of plasma cleared of the drug per unit time (C) [2 years]
Pharmacokinetics
Exploratory Biomarker: circulating tumor deoxyribonucleic acid (ctDNA) [2 years]
HCC-related pathway alterations including VEGF and TGF-β pathway genes

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Be willing and able to provide written informed consent for the trial;
Age ≥20 years male and female;
Subjects must have confirmed diagnosis of unresectable HCC with any of following criteria:

Histologically or cytologically confirmed diagnosis of HCC ii. Have Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy;

Have documented disease progression or intolerance after first-line systemic treatment;
At least one measurable lesion based on RECIST version 1.1 ;
Child-Pugh score ≤ 6 (Child-Pugh A)score within 7 days of first dose of study drug;
ECOG performance status: 0-1;
Have a predicted life expectancy of greater than 3 months;
The functions of the important organs are confirmed with the following requirement:

Hemoglobin (HGB) ≥ 90 g/L;
White blood cell count (WBC) ≥ 3×10^9/L；
Absolute neutrophil count (ANC) ≥ 1.5×10^9/L；
Platelets (PLT) ≥ 100×10^9/L；
Total bilirubin (TBIL) ≤ 1.5× Upper limit of normal value (ULN)
Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) ≤ 5× ULN
Creatinine (Cr) ≤ 1.5×ULN；
International normalization ratio (INR)or prothrombin time (PT) ≤ 1.5×ULN ;

Women must have a negative serum or urine pregnancy test within 72 hours prior to the start of investigational product;
Women of childbearing potential must agree to contraception for the duration of study treatment and 5 months after the last dose of study treatment;
Willing and able to comply with all aspects of the protocol

Exclusion Criteria:

Imaging findings for HCC corresponding to any of the following:

HCC with ≥ 50% liver occupation
Clear invasion into the bile duct
Portal vein invasion or thrombosis at the main portal branch (Vp4)

Gastric or esophageal varices that require treatment;
If prior history of DVT/PE, the patient needs to be on stable doses of anticoagulation with low molecular weight heparin or oral anticoagulant for at least two weeks;
Esophageal vein dilation, grade A of active peptic ulcer rating, and all bleeding risk by gastroscopy;
History of arterial thromboembolic event in past 6 months;
Active bleeding disorder, including gastrointestinal bleeding event or active hemoptysis within 28 days prior to study treatment;
Have central nervous system (CNS) metastases;
Has a known history of human immunodeficiency virus (HIV);
Has received prior immune checkpoint inhibitor (including those targeting PD-1, PD-L1 or PD-L2, CD137, or cytotoxic T-lymphocyte antigen [CTLA-4]);
Has a known history of, or any evidence of, interstitial lung disease or active non- infectious pneumonitis;
Has active autoimmune disease that has required systemic treatment in past 2 years;
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial;
Any history of drug or alcohol dependency or abuse within the prior 1 years;
Has known active Hepatitis B or Hepatitis C within 2 weeks prior to initiation of study treatment Note: Patients with HBV infection are required to be receiving effective antiviral therapy over two weeks, and then have continuous therapy in study period;
Pregnant, breast feeding, or planning to become pregnant;
Have a history of severe hypersensitivity reaction to monoclonal antibody;
Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug;
Have surgery, radiotherapy, ablation within one month before screening;
Subjects with any other serious disease considered by the investigator not in the condition to enter into the trial